With that in mind, let's take a closer look at Harvard Bioscience and see what CAPS investors are saying about the stock right now.

Harvard Biosciencefacts

Headquarters (founded)

Holliston, Mass. (1901)

Market Cap

$132.3 million

Industry

Life sciences tools and services

Trailing-12-Month Revenue

$112.0 million

Management

Chairman/CEO Chane GrazianoCFO Thomas McNaughton

Return on Equity (average, past 3 years)

11.1%

Cash/Debt

$20.3 million / $15.3 million

Competitors

Becton DickinsonBio-Rad LaboratoriesThermo Fisher Scientific

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 166 members who have rated Harvard Bioscience believe the stock will outperform the S&P 500 going forward.

This past weekend, one of those bulls, All-Star TMFDeej, helped bring the special opportunity to our community's attention:

Harvard Bioscience is in the process of spinning off its money-losing HART division, leaving behind a manufacturer of scientific instruments trading for only three times earnings, yet growing at 15% to 20% per year. See Jim Royal's great article on the situation for more information.

If you want to retire rich, you need to put together the best portfolio you can. Of course, despite its five-star rating, Harvard Bioscience may not be your top choice.